Delivery Order SPE2DB24D2205-SPE2DB25FEDWE
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Fingolimod 0.5 mg capsules (30-count units) with a ceiling value of $1,497.86. This competitive, non-set-aside award was executed on August 19, 2025, with an ultimate completion date of August 20, 2025, utilizing firm fixed-price pricing. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Fingolimod 0.5 mg capsules (30-count) with a ceiling value of $60,526.11. This is a firm fixed price, non-competitive delivery order that was awarded on August 22, 2025, with an ultimate completion date of August 25, 2025. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Fingolimod is a disease-modifying therapy used in the treatment of multiple...
- The Defense Logistics Agency awarded a delivery order valued at $21,634.02 to AmerisourceBergen Drug Corp for the supply of Fingolimod 0.5 mg capsules (30-count packages) with a completion date of August 1, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal vendor that...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Fingolimod 0.5 mg capsules (30-count units) with a contract ceiling value of $4,110.39. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 27, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a...
- The Defense Logistics Agency awarded a $5,394.00 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Fingolimod 0.5 mg capsules (30-count packages). This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion pharmaceutical prime vendor agreement running through December 2026. The award was made on a firm fixed-price basis with no set-aside designation,...
- The Defense Logistics Agency awarded a $10,360.75 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Fingolimod 0.5 mg capsules (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 22, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of FINGOLIMOD 0.5 MG CAPSULE 30S. The firm-fixed-price contract has a ceiling value of $20,347.96 and is set to expire on August 26, 2024. This contract award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through...
- This federal contract award, issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, is for the delivery of fingolimod 0.5 mg capsules. The contract is a firm fixed price delivery order with a ceiling value of $94,359.55 and a period of performance through March 27, 2024. Amerisourcebergen Drug Corp, through its Corporate Office division in Conshohocken, Pennsylvania, is the prime contractor on this award. The company is a subsidiary of Amerisourcebergen Corporation, a...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of FINGOLIMOD 0.5MG 30S, a prescription medication. The firm-fixed-price contract has a ceiling value of $9,019.86 and a completion date of July 2, 2025. This contract is not set aside and was awarded as an open competition. AmerisourceBergen Drug Corp is the prime contractor and holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with...
- This $36,982.83 firm-fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The contract is for the supply of FINGOLIMOD 0.5 MG CAPSULE 30S, a pharmaceutical product, with a completion date of October 9, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEDWEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Fingolimod 0.5 mg capsules (30-count units) under a firm fixed price contract valued at $30,185.00. The contract, awarded June 18, 2025, with completion targeted for June 20, 2025, represents a non-competitive set-aside award utilizing standard competitive procedures. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform all work at its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as a comprehensive vehicle for pharmaceutical and medical supply procurement supporting military healthcare systems globally. The IDC enables the company to supply an extensive range of medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare customers. Fingolimod, a disease-modifying therapy for multiple sclerosis, represents the type of specialized pharmaceutical product consistent with the broader medical supply mission of this strategic contracting vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $30.2k | 6/18/25 |